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OBJECTIVE — Pharmacological proﬁles of biphasic insulin aspart 30/70 (BIAsp 30) once
daily (OD), twice daily (b.i.d.), and three times daily (t.i.d.) were compared with other insulin
regimens in two crossover glucose clamp studies of insulin-treated type 2 diabetic patients.
RESEARCH DESIGNS AND METHODS — Study 1 consisted of BIAsp 30 OD, b.i.d.,
and t.i.d. versus biphasic human insulin 30/70 (BHI 30), OD (n  24). Study 2 examined BIAsp
30 t.i.d. versus basal-bolus therapy (insulin glargine OD plus insulin glulisine t.i.d.) (n  24).
Pharmacokinetics/pharmacodynamics (PK/PD) were investigated over 24 h.
RESULTS — Study 1: PK and PD were markedly different between BIAsp 30 OD and BHI 30
OD: the maximum insulin concentration and glucose infusion rate (GIR) were higher for BIAsp
30;timetomaximummetabolismwas1.7hsoonerforBIAsp30.Study2:bothregimensshowed
three distinct prandial-related GIR peaks. GIR 24-h area under the curve for BIAsp t.i.d. was
higher than for basal-bolus therapy: 2,585.2 vs. 2,289.2 mg/kg.
CONCLUSIONS — BIAsp had pharmacological advantages over BHI. BIAsp t.i.d. had a
similar PD proﬁle to basal-bolus therapy.
Diabetes Care 32:1431–1433, 2009
P
remixed insulin analogs are a com-
monly prescribed ﬁrst insulin ther-
apy for type 2 diabetic patients and
may be a simpler alternative to basal-
bolus therapy (1,2). Compared with bi-
phasichumaninsulin30/70(BHI30),the
modern premixed insulin analog, bipha-
sic insulin aspart 30/70 (BIAsp 30) has
pharmacokinetics (PK) that more closely
match endogenous insulin secretion
(3,4). Therefore, an initial once-daily
(OD) BIAsp 30 regimen can be safely in-
tensiﬁed to twice-daily (b.i.d.) or three-
times-daily (t.i.d.) injections (5). To
compare the PK and pharmacodynamic
(PD) proﬁles of these different regimens,
two crossover glucose clamp studies were
carried out in insulin-treated patients
with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— The randomized, open-
label, crossover clamp studies investi-
gated the PK/PD proﬁles of the following
regimens:
Study 1. BIAsp 30 OD, b.i.d., and t.i.d.
versus BHI 30 OD.
Study 2. BIAsp 30 t.i.d. versus basal-
bolus therapy (insulin glargine OD plus
insulin glulisine t.i.d.). All participants
had type 2 diabetes for 12 months and
were insulin treated for 3 months with
no oral therapy for 6 months.
In study 1, of 31 people screened, 24
were randomized (21 men, age 54.3 
5.5 years, BMI 32.2  3.2 kg/m
2, A1C
8.50.9%,insulindose0.70.2[range
0.3–1.1] units   kg
1   day
1). In study 2,
of 36 people screened, 24 were random-
ized (21 men, age 52.4  7.6 years, BMI
31.9  4.1 kg/m
2, A1C 8.7  1.1%, in-
sulin dose 0.7  0.1 [range 0.6–0.9]
units   kg
1   day
1).
All participants gave informed con-
sent. The study procedures were carried
out in accordance with the Declaration of
Helsinki.
Study designs and procedures
Study 1. Participants attended four sep-
arate study days (random order), 5–21
days apart, and received one, two, or
three injections of trial insulin at each vis-
it: OD 0.6 (I)U/kg of BHI 30 or BIAsp 30
administered at 1900 h; b.i.d. BIAsp 30
0.5 units/kg at 0700 h and 0.6 units/kg at
1900 h; t.i.d. BIAsp 30 0.5 units/kg
at 0700 h, 0.3 units/kg at 1300 h, and
0.6 units/kg at 1900 h. All were adminis-
tered subcutaneously and supplied in
3-ml Penﬁll cartridges (Novo Nordisk,
Denmark).
Study 2. Participants attended two sep-
arate study days (random order, with an
injection of the study drug the evening
before testing), 5–21 days apart. They re-
ceived injections of BIAsp 30 t.i.d. (total
0.72  0.12 units/kg, 40% of dose at
0700 h, 20% at 1300 h, and 40% at
1900 h) or insulin glulisine (total 0.29 
0.05 units/kg, 13.3% of total dose [0.1
units/kg] each at 0700 h, 1300 h, and
1900 h) plus insulin glargine (60% of
dose [0.44  0.07 units/kg] at 2300 h).
Eachparticipant’stotaldosewasthesame
for each regimen.
The glucose clamp procedure was
similar for both studies: at each dosing
visit, patients underwent a 24-h euglyce-
mic glucose clamp using a glucose-
controlled insulin infusion system
(Biostator; MTB Medizintechnik, Ger-
many) while fasting. Blood glucose was
clamped at 5.0 mmol/l by adjusting the
intravenous glucose infusion. Blood sam-
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insulin dosing and during the glucose
clamps for PK serum insulin measure-
ments.TheBiostatorrecordedPDglucose
infusion rates (GIRs) during the clamps.
Statistics. Regimens were compared us-
ing 24-h plots of serum insulin (not
shown for study 2) and GIR. Area under
the curve (AUC) measurements were
taken from insulin concentration time
plots and GIR time plots using the trape-
zoidal rule. Due to the different insulin
doses used, statistical analyses were per-
formed only on data from BIAsp 30
OD and BHI 30 OD (study 1, both 0.6
units/kg).
RESULTS— One participant with-
drew from each study, leaving 23 compl-
eters in each.
Study 1. The 24-h serum insulin and
GIR proﬁles of BHI 30 OD and BIAsp 30
OD, b.i.d., and t.i.d. showed marked dif-
ferences(Fig.1AandB).Maximumserum
insulin concentrations were greater for
BIAsp 30 than for BHI 30 (73.1–100.4
mU/l [ﬁrst injection of each regimen] vs.
46.7 mU/l, respectively). Time to maxi-
mum serum insulin concentration was
shorterforBIAsp30thanforBHI30(2.1–
2.6 h [ﬁrst injection of each regimen] vs.
3.2 h, respectively). The insulin AUC24h
for BIAsp 30 OD was greater than for BHI
30 OD. The AUC24h for the BIAsp 30 reg-
imens reﬂected total insulin dose: OD
(0.6 units/kg) 668.1  191.0 mU   1
1  
h
1;b.i.d.(1.1units/kg)1,123.5280.0
mU   l
1   h
1, t.i.d. (1.4 units/kg)
1,405.0  329.7 mU   l
1   h
1.
Maximum GIR was signiﬁcantly
higher for BIAsp 30 OD than for BHI 30
OD (3.7 vs. 2.9 mg   kg
1   min
1; P 
0.0030); time to maximum effect was
5.2 h postinjection for BIAsp 30 OD and
5.7 h for BHI 30 OD (P  0.0855).
Study 2. The 24-h GIR proﬁles of BIAsp
t.i.d. and basal-bolus therapy (insulin
glargine OD/glulisine t.i.d.) showed three
distinct peaks reﬂecting prandial injections
(Fig.1C).MaximumGIRwassimilarforBI-
Asp 30 t.i.d. and basal-bolus therapy fol-
lowing the ﬁrst two injections but larger for
BIAsp 30 after the third: 0700 h, 2.55 vs.
2.42 mg   kg
1   min
1; 1300 h, 2.47 vs.
2.77 mg   kg
1   min
1; 1900 h, 3.52
vs. 2.70 mg   kg
1   min
1. Maximum
effect was reached in slightly less time
for basal-bolus therapy: 0700 h, 3.09
vs. 2.61 h; 1300 h, 2.77 vs. 2.65 h;
1900 h, 3.68 vs. 3.35 h. The GIR
AUC24h for BIAsp 30 t.i.d. was slightly
higher than for basal-bolus therapy:
2,585.2  1,165 vs. 2,289.2  1,095
mg/kg.
CONCLUSIONS — The PK and PD
proﬁles of BHI 30 and BIAsp 30 OD,
b.i.d., and t.i.d. were well characterized.
BIAsp 30 OD had pharmacological ad-
vantages over BHI 30 OD (earlier and
higher serum insulin levels), which may
confergreaterpostprandialglycemiccon-
trol (3,6–8). During the 24-h clamp, se-
rum insulin following BIAsp 30 OD and
BHI30ODreturnedtosimilarlevels,sug-
gesting that the duration of action of pro-
taminated aspart is similar to that of NPH
insulin (3,4).
BIAsp 30 t.i.d. gave a similar PD pro-
ﬁle to that of basal-bolus therapy with in-
sulin glargine/glulisine and demonstrated
slightly greater overall metabolic effect at
the same total dose, possibly due to the
higherGIRfollowingthethirddailyinjec-
tion. This greater glucose-lowering effect
with BIAsp 30 during the evening/
nighttime may pose an increased risk of
nocturnal hypoglycemia, so careful titra-
tion of the evening injection is needed. If
these pharmacological results can be con-
ﬁrmed in a clinical trial, BIAsp 30 t.i.d.
may represent an alternative to basal-
bolus therapy requiring at least one fewer
daily injection.
Figure 1—PK and PD proﬁles following injections of test insulins in two studies in patients with
type 2 diabetes, obtained using a euglycemic clamp procedure. A: Study 1: 24-h serum insulin
proﬁlesduringwhichpatientsreceivedBIAsp30once(1900h),twice(0700and1900h),orthree
times (0700, 1300, and 1900 h) daily, or BHI 30 once daily (1900 h). The 24-h proﬁles have been
overlainforeaseofcomparison.B:Study1:24-hGIRproﬁlesduringwhichpatientsreceivedBIAsp
30once(1900h),twice(0700and1900h),orthreetimes(0700,1300,and1900h)daily,orBHI
30 once daily (1900 h). The 24-h proﬁles have been overlain for ease of comparison. C: Study 2:
24-h GIR proﬁles during which patients received BIAsp 30 three times daily (0700, 1300, and
1900 h) or basal-bolus therapy using insulin glargine once daily (2300 h on the day before the
clampandagainonthedayoftheclamp)plusinsulinglulisinethreetimesdaily(0700,1300,and
1900 h).
Biphasic insulin aspart
1432 DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009Acknowledgments— T.H.isashareholderin
Proﬁl Institut fu ¨r Stoffwechselforschung
GmbH, which has received grants from phar-
maceutical companies including Eli Lilly,
sanoﬁ-aventis, and Novo Nordisk. He has also
received speaking honoraria from sanoﬁ-
aventis and Novo Nordisk and is an advisory
board member for Novo Nordisk. H.H. and
K.O. are employees of Novo Nordisk; H.H.
alsoholdsstockinNovoNordisk.Theauthors
thank Dr. Scott Gouveia and Dr. Catherine
Jones of Watermeadow Medical, U.K., for
their editorial assistance, which was sup-
ported by Novo Nordisk. No other potential
conﬂictsofinterestrelevanttothisarticlewere
reported.
The data in this paper have not been previ-
ously published.
References
1. Hermansen K, Fontaine P, Kukolja KK,
Peterkova V, Leth G, Gall MA. Insulin an-
alogues (insulin detemir and insulin as-
part) versus traditional human insulins
(NPH insulin and regular human insulin)
in basal-bolus therapy for patients with
Type 1 diabetes. Diabetologia 2004;47:
622–629
2. Liebl A, Prager R, Binz K, Kaiser M, Ber-
genstal R, Gallwitz B; PREFER Study
Group. Comparison of insulin analogue
regimens in people with type 2 diabetes
mellitus in the PREFER Study: a random-
izedcontrolledtrial.DiabetesObesMetab
2009;11:45–52
3. Weyer C, Heinemann L, Heise T. Insulin
aspart in a 30/70 premixed formulation.
Pharmacodynamic properties of a rapid-
acting insulin analog in stable mixture.
Diabetes Care 1997;20:1612–1614
4. Jacobsen LV, Søgaard B, Riis A. Pharma-
cokinetics and pharmacodynamics of a
premixed formulation of soluble and pro-
tamine-retarded insulin aspart. Eur J Clin
Pharmacol 2000;56:399–403
5. Garber AJ, Wahlen J, Wahl T, Bressler P,
Braceras R, Allen E, Jain R. Attainment of
glycaemic goals in type 2 diabetes with
once-,twice-,orthrice-dailydosingwithbi-
phasic insulin aspart 70/30 (The 1–2-3
study). Diabetes Obes Metab 2006;8:
58–66
6. Home PD, Lindholm A, Riis A; European
Insulin Aspart Study Group. Insulin aspart
vs. human insulin in the management of
long-term blood glucose control in Type 1
diabetes mellitus: a randomized controlled
trial. Diabet Med 2000;17:762–770
7. Rosenfalck AM, Thorsby P, Kjems L, Bir-
kelandK,DejgaardA,HanssenKF,Mads-
bad S. Improved postprandial glycaemic
control with insulin aspart in type 2 dia-
betic patients treated with insulin. Acta
Diabetol 2000;37:41–46
8. Bretzel RG, Arnolds S, Medding J, Linn T.
A direct efﬁcacy and safety comparison of
insulin aspart, human soluble insulin,
and human premix insulin (70/30) in pa-
tients with type 2 diabetes. Diabetes Care
2004;27:1023–1027
Heise and Associates
DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009 1433